Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study assessing VIR7229

Next Previous
Trial Profile

Phase 1 study assessing VIR7229

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VIR 7229 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions

Most Recent Events

  • 22 Feb 2024 According to Vir Biotechnology media release, later this year, company expects to file a health authority application to support a Phase 1 trial evaluating VIR-7229. The development of VIR-7229 has been supported in whole or in part with federal funds from the Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).
  • 02 Nov 2023 According to Vir Biotechnology media release, the Company expects to initiate a Phase 1 clinical trial in 2024.
  • 10 Oct 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top